MARIETTA, Ga., Aug. 29, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today an update to its intellectual property portfolio.
The '077 patent expands the portfolio of MiMedx patents related to the Company's proprietary methodology for the linear organization of natural collagen fibers to form the mechanical construct for optimal stiffness and strength to treat orthopedic and other conditions such as tendon repair. The '800; '801; '005; '003; and '074 patents further add to the portfolio of patents issued to the Company for its proprietary methodology of preparing placental membrane tissue grafts for medical use.
Parker H. "Pete" Petit, Chairman and CEO, said, "We are continually creating and developing new intellectual property as well as adding to our portfolio of patents that protect our existing intellectual property. At present, the Company's robust patent portfolio consists of 33 amniotic and placental patents issued and allowed, and nearly 100 amniotic patent applications pending with the U.S Patent and Trademark Office. Counting all of the MiMedx technologies, we currently have over 200 patents issued or pending."
Bill Taylor, President and COO, added, "We are strongly resolute in enforcing our rights when our patents are infringed upon. Often, this includes complex and costly litigation; however, this is essential if we want to protect our intellectual property to the fullest extent."
MiMedx also announced today that a finding has been rendered from the Patent Trial and Appeal Board ("PTAB") of the United States Patent and Trademark Office regarding MiMedx's United States Patent No. 8,372,437. As with the PTAB's recent ruling on the '687 embossment patent, the PTAB ruled that the '437 patent was invalid based on alleged prior art rendering it obvious. This '437 patent is not primary to MiMedx's proprietary processing of amniotic tissues, which processing preserves the cytokines, growth factors, proteins and other critical factors that enhance the clinical performance of the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts.
Petit stated, "The ancillary '437 patent is simply one among our robust patent portfolio, and this decision has zero impact on any of our other issued patents and pending applications. Most importantly, the PTAB finding on the '437 patent has no bearing on our cornerstone EpiFix® and AmnioFix® patents, the 8,709,494 and 8,323,701 patents, respectively. The validity of these patents was recently upheld by the PTAB. In addition, it should be noted that the PTAB's decision utilized a far broader standard for construing claims than what is utilized in federal courts. We believe that standard undoubtedly led to the flawed outcome. And, while the '437 patent is by no means one of our primary patents, we believe the decision is fundamentally incorrect and we plan to appeal."
"We have other claims more relevant to product effectiveness and efficacy that are embedded in our other patents covering the topics included in the broad '437 patent. The PTAB ruling does not affect our active district court litigations on the cornerstone EpiFix® and AmnioFix® patents, in which Musculoskeletal Transplant Foundation, Inc. ("MTF"), Liventa Bioscience, Inc. and Medline Industries, Inc. are defendants in the one case, and Transplant Technology, Inc. d/b/a Bone Bank Allografts and Texas Human Biologics, Ltd., are defendants in the other case. Those lawsuits remain pending with upcoming trials. As mentioned in our August 11, 2016 press release, the strength of our patent portfolio and the upheld validity of our cornerstone patents contribute to our high confidence for the successful outcome of our pending lawsuits," noted Taylor.
Petit added, "We are working diligently to bring our patent litigation to closure and look forward to reporting to shareholders positive results from these first trials. Some of these litigation issues can be quite complex so we will continue to inform shareholders of relevant actions. The key issue is that if we are successful in these trials, we will have access to injunctive relief in terms of stopping other competitors from selling products that infringe our patents. We will then be able to proceed against other violators of our patents and seek injunctive relief to stop their distribution of these infringing products."
"Businesses ultimately succeed or fail through competition in the marketplace. We have proven our ability to compete and win in the marketplace with our products over the last five years. However, as a patent holder, we also believe it is worth investing time and expense on the legal front as well to protect the extensive effort that we have put into the development of our patents," concluded Petit.Editor's Details
Last updated on: 29/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.